Bristol Myers Squibb (BMY) Competitors

Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Do institutionals & insiders have more ownership in AMGN or BMY?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more volatility and risk, AMGN or BMY?

Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Bristol Myers Squibb has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Does the media refer more to AMGN or BMY?

In the previous week, Amgen had 6 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 54 mentions for Amgen and 48 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.26 beat Amgen's score of 1.18 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	42 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Bristol Myers Squibb	35 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts prefer AMGN or BMY?

Amgen currently has a consensus price target of $304.43, suggesting a potential upside of 8.70%. Bristol Myers Squibb has a consensus price target of $56.38, suggesting a potential upside of 17.63%. Given Bristol Myers Squibb's higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.32
Bristol Myers Squibb	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Is AMGN or BMY more profitable?

Amgen has a net margin of 18.96% compared to Bristol Myers Squibb's net margin of 10.58%. Amgen's return on equity of 174.71% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	18.96%	174.71%	13.12%
Bristol Myers Squibb	10.58%	80.04%	14.69%

Which has stronger earnings and valuation, AMGN or BMY?

Amgen has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.51	$4.09B	$12.23	22.90
Bristol Myers Squibb	$48.30B	2.02	-$8.95B	$2.48	19.33

Is AMGN or BMY a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.4%. Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.2%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Bristol Myers Squibb on 13 of the 19 factors compared between the two stocks.